Auto-injectors Market, by Product Type (Prefilled Auto-injectors, Fillable Auto-injectors), by Disease Indication (Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Others (Diabetes, Psoriasis, etc.)), by Distribution Channel (Hospital Pharmacies, Re

Auto-injectors Market, by Product Type (Prefilled Auto-injectors, Fillable Auto-injectors), by Disease Indication (Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Others (Diabetes, Psoriasis, etc.)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Auto- injector is a medical device which can deliver dose of medications. Auto injectors are easy to use and self-administration by patients is possible. Auto-injectors are disposable and there is a tremendous growth in the development of reusable auto-injectors with multiple dosing. Auto-injectors come under injectable drug delivery which is considered as the most effective route of administration for the effective delivery of drugs to the targeted site, which enhances the patient’s compliance to the drug. The Injectable delivery enhances the rapid absorption of drug from various sites such as subcutaneous, intravenous, and intramuscular. The injectable delivery increases the bioavailability of the drug at the systemic circulation, which offers availability of drug at intended site of action. Epinephrine auto-injector is a type of auto-injector widely used for people at risk of anaphylaxis. Auto-injectors enclose prefilled syringes or cartridges which are driven by a spring system. Auto-injectors are often used in the military to protect personnel from chemical warfare agents.

Market Dynamics

Adoption of inorganic growth strategies such as product launch by key market players is expected to drive the global auto-injectors market over the forecast period. For instance, in April 2020, Teva Pharmaceutical Industries Ltd., a pharmaceutical company, announced that they had launched auto-injector for AJOVY, which is indicated for the preventive treatment of migraine in adults. This new auto-injector has several features such as easy handling including a button-free, push-down mechanism, audible cues that signal progress of administration, and a window that displays when the dose has been delivered.

Key features of the study:

• This report provides an in-depth analysis of the global auto-injectors market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global auto-injectors market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Becton, Dickinson and Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Xeris Biopharma Holdings Inc., BlackHagen Design, GSK plc., Genentech, Inc., AstraZeneca, Owen Mumford Ltd., Stevanato Group, Jabil Inc., Pfizer, Inc., Mylan N.V., Novartis AG, Bayer AG, Janssen Pharmaceuticals, Inc., Antares Pharma, Eli Lilly and Company, Amgen Inc., Rafa Laboratories Ltd., Halozyme, Inc., Biogen, and Teva Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global auto-injectors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global auto-injectors market

Detailed Segmentation:

• Global Auto-injectors Market, By Product Type:
• Prefilled Auto-injectors
• Fillable Auto-injectors
• Global Auto-injectors Market, By Disease Indication:
• Anaphylaxis
• Multiple Sclerosis
• Rheumatoid Arthritis
• Others (Diabetes, Psoriasis, etc.)
• Global Auto-injectors Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Auto-injectors Market, By Region:
• North America

By Country

• U.S.
• Canada
• Latin America

By Country

• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe

By Country

• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific

By Country

• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East

By Country

• GCC
• Israel
• Rest of Middle East
• Africa

By Region/Country

• South Africa
• Central Africa
• North Africa
• Company Profiles
• Becton, Dickinson and Company*

Company Highlights

Products Portfolio

Key Highlights

Financial Performance

Strategies

• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Xeris Biopharma Holdings Inc.
• BlackHagen Design
• GSK plc.
• Genentech, Inc.
• AstraZeneca
• Owen Mumford Ltd.
• Stevanato Group
• Jabil Inc.
• Pfizer, Inc.
• Mylan N.V.
• Novartis AG
• Bayer AG
• Janssen Pharmaceuticals, Inc.
• Antares Pharma
• Eli Lilly and Company
• Amgen, Inc.
• Rafa Laboratories Ltd.
• Halozyme, Inc.
• Biogen
• Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.